Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961411 | 0.81 | TGFBR1 (0.37) | TGFBR1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL22270959 | 0.78 | TGFBR1 (0.43) | TGFBR1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2596736 | 0.77 | TGFBR1 (0.37) | TGFBR1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2596841 | 0.77 | TGFBR1 (0.40) | TGFBR1KDM4EALDH1A1MAPT | |
| SCHEMBL2596784 | 0.77 | DYRK1A (0.33) | ADORA2AADORA1 | |
| SCHEMBL22387259 | 0.74 | TGFBR1 (0.36) | TGFBR1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26719952 | 0.74 | TGFBR1 (0.36) | TGFBR1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2596927 | 0.72 | PDE4D (0.39) | — | |
| SCHEMBL2596807 | 0.71 | JAK2 (0.32) | TGFBR1 | |
| SCHEMBL2596894 | 0.69 | TGFBR1 (0.33) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | TGFBR1 413/4885ADORA3 329/4885ADORA2A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.